OBJECTIVE: To describe an early experience of treating 40 children with the dual endothelin receptor antagonist bosentan, which is known to be safe and effective in adults with pulmonary hypertension (PH). DESIGN: In this retrospective, observational study the UK Service for Pulmonary Hypertension for children treated 40 children with bosentan, 20 with idiopathic pulmonary arterial hypertension (IPAH) (mean age 8.03 years, range 1.2-17) and 20 with PH associated with other conditions (congenital heart disease, parenchymal lung or connective tissue disease, or HIV). Their mean age was 8.3 years (range 0.6-16 years). PATIENTS: 39 patients were in World Health Organization (WHO) class III and IV, and all had shown recent deterioration. In IPAH the mean pulmonary vascular resistance (PVR) was 21.7 units.m2 (range 5.6-42.8). In secondary PH the mean PVR was 18 units.m2 (range 4.9-49). No child had a positive response to vasodilator testing with nitric oxide. INTERVENTIONS: Bosentan was given as first line treatment to 25. Nine were given intravenous epoprostenol. Children were treated for a mean of 12.7 months (range 2-24 months). MAIN OUTCOME MEASURES: Response to treatment was judged by WHO functional class, six minute walk test, weight, ECG and echocardiographic findings, and need to add additional treatment. RESULTS: Bosentan was well tolerated. In the IPAH group 19 (95%) stabilised with bosentan treatment but 12 (60%) patients needed combined treatment with epoprostenol. In secondary PH, WHO class, six minute walk test, and weight gain improved significantly. CONCLUSION: Bosentan helped stabilise children with IPAH but intravenous epoprostenol was also needed by 60%. Children with secondary PH improved.
OBJECTIVE: To describe an early experience of treating 40 children with the dual endothelin receptor antagonist bosentan, which is known to be safe and effective in adults with pulmonary hypertension (PH). DESIGN: In this retrospective, observational study the UK Service for Pulmonary Hypertension for children treated 40 children with bosentan, 20 with idiopathic pulmonary arterial hypertension (IPAH) (mean age 8.03 years, range 1.2-17) and 20 with PH associated with other conditions (congenital heart disease, parenchymal lung or connective tissue disease, or HIV). Their mean age was 8.3 years (range 0.6-16 years). PATIENTS: 39 patients were in World Health Organization (WHO) class III and IV, and all had shown recent deterioration. In IPAH the mean pulmonary vascular resistance (PVR) was 21.7 units.m2 (range 5.6-42.8). In secondary PH the mean PVR was 18 units.m2 (range 4.9-49). No child had a positive response to vasodilator testing with nitric oxide. INTERVENTIONS:Bosentan was given as first line treatment to 25. Nine were given intravenous epoprostenol. Children were treated for a mean of 12.7 months (range 2-24 months). MAIN OUTCOME MEASURES: Response to treatment was judged by WHO functional class, six minute walk test, weight, ECG and echocardiographic findings, and need to add additional treatment. RESULTS:Bosentan was well tolerated. In the IPAH group 19 (95%) stabilised with bosentan treatment but 12 (60%) patients needed combined treatment with epoprostenol. In secondary PH, WHO class, six minute walk test, and weight gain improved significantly. CONCLUSION:Bosentan helped stabilise children with IPAH but intravenous epoprostenol was also needed by 60%. Children with secondary PH improved.
Authors: Gideon A Paul; J Simon R Gibbs; Alan R Boobis; Allifia Abbas; Martin R Wilkins Journal: Br J Clin Pharmacol Date: 2005-07 Impact factor: 4.335
Authors: Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau Journal: N Engl J Med Date: 2002-03-21 Impact factor: 91.245
Authors: R N Channick; G Simonneau; O Sitbon; I M Robbins; A Frost; V F Tapson; D B Badesch; S Roux; M Rainisio; F Bodin; L J Rubin Journal: Lancet Date: 2001-10-06 Impact factor: 79.321
Authors: Michael A Gatzoulis; Paula Rogers; Wei Li; Carl Harries; Derek Cramer; Simon Ward; Ghada W Mikhail; J Simon R Gibbs Journal: Int J Cardiol Date: 2005-01 Impact factor: 4.164
Authors: Hilario Nunes; Marc Humbert; Olivier Sitbon; Jane H Morse; Zemin Deng; James A Knowles; Catherine Le Gall; Florence Parent; Gilles Garcia; Philippe Hervé; Robyn J Barst; Gérald Simonneau Journal: Am J Respir Crit Care Med Date: 2003-02-25 Impact factor: 21.405
Authors: Olivier Sitbon; Virginie Gressin; Rudolf Speich; Peter S Macdonald; Milos Opravil; David A Cooper; Thierry Fourme; Marc Humbert; Jean-François Delfraissy; Gérald Simonneau Journal: Am J Respir Crit Care Med Date: 2004-08-18 Impact factor: 21.405
Authors: Olivier Sitbon; David B Badesch; Richard N Channick; Adaani Frost; Ivan M Robbins; Gérald Simonneau; Victor F Tapson; Lewis J Rubin Journal: Chest Date: 2003-07 Impact factor: 9.410
Authors: Abraham Rothman; Robert G Wiencek; Stephanie Davidson; William N Evans; Humberto Restrepo; Valeri Sarukhanov; Amanda Rivera-Begeman; David Mann Journal: Comp Med Date: 2011-06 Impact factor: 0.982
Authors: Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2006-09 Impact factor: 3.000